Clinical and molecular characteristics of NUP98/NSD1-positive versus -negative cases
| . | NUP98/NSD1-positive cases . | NUP98/NSD1-negative cases . | P . |
|---|---|---|---|
| Total, N (%) | 23 (2.1) | 1078 (97.9) | |
| Pediatric cohort | 13 (4.4) | 280 (95.6) | .001 |
| Adult cohort | 10 (1.2) | 798 (98.8) | |
| Age, y | .004 | ||
| Median | 16.8 | 40.0 | |
| Range | 2.3-63.0 | 0.0-77.0 | |
| Sex, % | 0.21 | ||
| Female | 34.8 | 48.0 | |
| Male | 65.2 | 52.0 | |
| WBC, × 109/L (N = 1071) | < .001 | ||
| Median | 146.5 | 26.2 | |
| Range | 6.1-377.6 | 0.3-510.0 | |
| FAB type, N (%) | .26 | ||
| M0 | 54 (5.0) | ||
| M1 | 3 (13.0) | 193 (17.9) | .13* |
| M2 | 3 (13.0) | 260 (24.1) | |
| M3 | 42 (3.9) | ||
| M4 | 8 (34.8) | 208 (19.3) | .01† |
| M5 | 7 (30.4) | 215 (19.9) | |
| M6 | 21 (1.9) | ||
| M7 | 11 (1.0) | ||
| RAEB/RAEB-t | 49 (4.5) | ||
| Other | 2 (0.2) | ||
| Missing | 2 (8.7) | 23 (2.1) | |
| Karyotype, N (%) | .004 | ||
| t(8;21) | 74 (6.9) | ||
| inv(16) | 91 (8.4) | ||
| t(15;17) | 39 (3.6) | ||
| 11q23 | 87 (8.1) | ||
| CN-AML | 18 (78.3) | 388 (36.0) | |
| Other | 5 (21.7) | 355 (32.9) | |
| Missing | 44 (4.1) | ||
| Mutations, N (%) | |||
| NPM1 (n = 1084) | 263 (24.8) | .006 | |
| CEBPA (n = 268)‡ | 15 (5.9) | > .99 | |
| MLL-PTD (n = 244)‡ | 6 (2.6) | > .99 | |
| FLT3-ITD (n = 1089) | 21 (91.3) | 234 (22.0) | < .001 |
| FLT3-TKD (n = 1072) | 88 (8.4) | .25 | |
| N-RAS (n = 1069) | 1 (4.3) | 146 (14.0) | .35 |
| KIT (n = 280)‡ | 20 (7.5) | .61 | |
| PTPN11 (n = 280)‡ | 4 (1.5) | > .99 | |
| WT1 (n = 680) | 9 (45.0) | 46 (7.0) | < .001 |
| IDH1 (n = 808)§ | 50 (6.3) | > .99 | |
| IDH2 (n = 808)§ | 91 (11.4) | 0.61 | |
| . | NUP98/NSD1-positive cases . | NUP98/NSD1-negative cases . | P . |
|---|---|---|---|
| Total, N (%) | 23 (2.1) | 1078 (97.9) | |
| Pediatric cohort | 13 (4.4) | 280 (95.6) | .001 |
| Adult cohort | 10 (1.2) | 798 (98.8) | |
| Age, y | .004 | ||
| Median | 16.8 | 40.0 | |
| Range | 2.3-63.0 | 0.0-77.0 | |
| Sex, % | 0.21 | ||
| Female | 34.8 | 48.0 | |
| Male | 65.2 | 52.0 | |
| WBC, × 109/L (N = 1071) | < .001 | ||
| Median | 146.5 | 26.2 | |
| Range | 6.1-377.6 | 0.3-510.0 | |
| FAB type, N (%) | .26 | ||
| M0 | 54 (5.0) | ||
| M1 | 3 (13.0) | 193 (17.9) | .13* |
| M2 | 3 (13.0) | 260 (24.1) | |
| M3 | 42 (3.9) | ||
| M4 | 8 (34.8) | 208 (19.3) | .01† |
| M5 | 7 (30.4) | 215 (19.9) | |
| M6 | 21 (1.9) | ||
| M7 | 11 (1.0) | ||
| RAEB/RAEB-t | 49 (4.5) | ||
| Other | 2 (0.2) | ||
| Missing | 2 (8.7) | 23 (2.1) | |
| Karyotype, N (%) | .004 | ||
| t(8;21) | 74 (6.9) | ||
| inv(16) | 91 (8.4) | ||
| t(15;17) | 39 (3.6) | ||
| 11q23 | 87 (8.1) | ||
| CN-AML | 18 (78.3) | 388 (36.0) | |
| Other | 5 (21.7) | 355 (32.9) | |
| Missing | 44 (4.1) | ||
| Mutations, N (%) | |||
| NPM1 (n = 1084) | 263 (24.8) | .006 | |
| CEBPA (n = 268)‡ | 15 (5.9) | > .99 | |
| MLL-PTD (n = 244)‡ | 6 (2.6) | > .99 | |
| FLT3-ITD (n = 1089) | 21 (91.3) | 234 (22.0) | < .001 |
| FLT3-TKD (n = 1072) | 88 (8.4) | .25 | |
| N-RAS (n = 1069) | 1 (4.3) | 146 (14.0) | .35 |
| KIT (n = 280)‡ | 20 (7.5) | .61 | |
| PTPN11 (n = 280)‡ | 4 (1.5) | > .99 | |
| WT1 (n = 680) | 9 (45.0) | 46 (7.0) | < .001 |
| IDH1 (n = 808)§ | 50 (6.3) | > .99 | |
| IDH2 (n = 808)§ | 91 (11.4) | 0.61 | |